Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

Japanese R&D of autoimmune disorder medicines company seeks USD 12m pre-IPO financing.

Project region Japan
Industry Biomedicine
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365


  • Simon Laube

    Simon Laube

    Senior Associate, International Business Advisory

Project highlights autoimmune disorders medicines - Phase II clinical trial - USD 33 m secured
Project description

The Japanese company is mainly engaged in R&D of medicines for autoimmune disorders and is also preparing to carry out R&D of cancer medicines related to harmonic T cells. At present, one of the two medicines in the pipeline has entered Phase II clinical trial. The company was restructured in 2018 and registered in Taiwan. Its total investment exceeds USD 33 million. It seeks pre-IPO financing of USD 12 million (USD 5 million has been injected), and then plans to be listed in Taiwan in 2023.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive